Publications by authors named "N Hatori"
Objectives: This study aimed to investigate the relationship between microvascular status in the non-ischemic myocardium and the diagnostic performance of stress dynamic CT perfusion imaging (CTP) in detecting hemodynamically significant stenosis.
Materials And Methods: This study included 157 patients who underwent coronary computed tomography angiography (CTA), CTP, and invasive coronary angiography (ICA), including fractional flow reserve (FFR). Hemodynamically significant stenosis was defined by FFR and ICA.
Aim: To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide 1 receptor agonist (GLP-1RA) combination therapy, focusing only on those patients who had chronic kidney disease (CKD), to examine whether the composite renal outcome differed between those who received SGLT2 inhibitor treatment first and those who received a GLP-1RA first.
Methods: We included 438 patients with CKD (GLP-1RA-first group, n = 223; SGLT2 inhibitor-first group, n = 215) from the 643 T2D patients in the RECAP study. The incidence of the composite renal outcome, defined as progression to macroalbuminuria and/or a ≥50% decrease in estimated glomerular filtration rate (eGFR), was analysed using a propensity score (PS)-matched model.
Article Synopsis
- SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) both show protective effects for patients with diabetic kidney disease, often used in combination for type 2 diabetes (T2D).
- A study involving 643 T2D patients examined differences in annual eGFR decline based on whether patients started with SGLT2i or GLP1Ra.
- Results indicated that those starting with SGLT2i had a significantly smaller decline in eGFR after adding GLP1Ra, while the reverse pairing showed no significant change, suggesting the preceding drug influences the renal benefits of the combination therapy.
Article Synopsis
- A study evaluated the effects of the order in which patients received sodium-glucose cotransporter inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1Ras) on kidney health in type 2 diabetes patients.
- Researchers analyzed data from 643 patients who underwent at least one year of treatment and assessed kidney function based on albuminuria status and glomerular filtration rate (eGFR).
- The findings indicated no significant difference in kidney outcomes between those who started with SGLT2is vs. GLP1Ras, suggesting that the sequence of medication administration does not impact renal health.
Sodium-glucose cotransporter 2 inhibitor (SGLT2-I) shows excellent antihypertensive effects in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the antihypertensive effect of SGLT2-I remains unknown. We investigated the impact of baseline BMI on the achievement of target blood pressure (BP) with SGLT2-I treatment in Japanese patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD).
View Article and Find Full Text PDF